These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20510167)

  • 1. [The experience of anti-TNF-alpha registries and observatories].
    Sibilia J; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):18-21. PubMed ID: 20510167
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab: new indication. A last resort for treating plaque psoriasis: just another TNF alpha antagonist.
    Prescrire Int; 2008 Dec; 17(98):240. PubMed ID: 19422152
    [No Abstract]   [Full Text] [Related]  

  • 3. [Infectious risks of immunomodulating therapies in rheumatology].
    Van Delden C
    Rev Med Suisse; 2006 Mar; 2(57):738-40, 743-5. PubMed ID: 16604876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
    Girolomoni G; Abeni D
    Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
    [No Abstract]   [Full Text] [Related]  

  • 5. Developments in systemic immunomodulatory therapy for psoriasis.
    Berger EM; Gottlieb AB
    Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy.
    Cassano N; Coviello C; Loconsole F; Miracapillo A; Vena GA
    Eur J Dermatol; 2006; 16(3):316-7. PubMed ID: 16709508
    [No Abstract]   [Full Text] [Related]  

  • 7. Primary varicella-zoster infection in patients on biologic therapies for psoriasis.
    Hackett CB; Kirby B
    Br J Dermatol; 2010 Nov; 163(5):1122. PubMed ID: 20633011
    [No Abstract]   [Full Text] [Related]  

  • 8. Etanercept in psoriasis treatment.
    Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to manage infections in the era of biologics?
    Saraceno R; Chimenti S
    Dermatol Ther; 2008; 21(3):180-6. PubMed ID: 18564248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
    Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM
    Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283
    [No Abstract]   [Full Text] [Related]  

  • 12. How to evaluate the benefit-risk profile of newly marketed drugs.
    Naldi L
    Ann Dermatol Venereol; 2010 Apr; 137(4):264-6, 261-3. PubMed ID: 20417357
    [No Abstract]   [Full Text] [Related]  

  • 13. [Safety of biological therapies: new data from BIOBADASER].
    Rodríguez Lozano C
    Reumatol Clin; 2011 Mar; 6S3():S1-6. PubMed ID: 21794763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors for patients with severe psoriasis.
    Dharamsi JW; Bhosle M; Balkrishnan R; Yentzer BA; Feldman SR
    Br J Dermatol; 2009 Sep; 161(3):605-16. PubMed ID: 19438475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.
    Menon K; Van Voorhees AS; Bebo BF; Gladman DD; Hsu S; Kalb RE; Lebwohl MG; Strober BE;
    J Am Acad Dermatol; 2010 Feb; 62(2):291-9. PubMed ID: 19646777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
    Prescrire Int; 2008 Aug; 17(96):137. PubMed ID: 19480092
    [No Abstract]   [Full Text] [Related]  

  • 18. [A new view of psoriasis].
    Jullien D; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):3-7. PubMed ID: 20510168
    [No Abstract]   [Full Text] [Related]  

  • 19. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
    Strangfeld A; Listing J
    Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reumáticas (GENTE)].
    Díaz-Jouanen E; Abud-Mendoza C; Garza-Elizondo MA; Medrano-Ramírez G; Burgos-Vargas R; Orozco-Alcalá JJ; Pacheco-Tena CF; Pineda C; Pozos-Espíndola JC; Ramos-Niembro F; Robles-San-Román M; Santana-Sahagún JE;
    Rev Invest Clin; 2009; 61(3):252-66. PubMed ID: 19736814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.